ONC 841
Alternative Names: Anti-SIGLEC10 antibody - OncoC4; ONC-841Latest Information Update: 06 Sep 2024
At a glance
- Originator OncoImmune
- Developer OncoC4
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; SIGLEC10 protein inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours